Astrazeneca vs Merck: revenue, profit, margins and growth compared
Astrazeneca brought in $58.7B of revenue in fiscal 2025, Merck $65B in fiscal 2025. Revenue changed by +8.6% at Astrazeneca and +1.3% at Merck on the year before, so Astrazeneca grew faster. Astrazeneca kept 17.4% of its revenue as net profit, Merck 28.1%. Free cash flow was $11.8B at Astrazeneca and $12.4B at Merck.
Fiscal years as each company reports them; the two may end in different months.
Questions about Astrazeneca and Merck
Which is bigger by revenue, Astrazeneca or Merck?
Merck is bigger by revenue: $65B in fiscal 2025, against $58.7B for Astrazeneca in fiscal 2025.
Which keeps more of its revenue as profit, Astrazeneca or Merck?
Astrazeneca had a net margin of 17.4% in fiscal 2025; Merck had 28.1% in fiscal 2025.
Which grew revenue faster, Astrazeneca or Merck?
In their latest fiscal years revenue changed by +8.6% at Astrazeneca and +1.3% at Merck.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.